Cholangiocarcinoma laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) |
||
Line 30: | Line 30: | ||
*[[CA 19-9]] is a protein released by cancers of the pancreas and bile ducts.<ref name="pmid15621994">{{cite journal |vauthors=Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, Suh KS, Lee KU, Park YH |title=Actual long-term outcome of extrahepatic bile duct cancer after surgical resection |journal=Ann. Surg. |volume=241 |issue=1 |pages=77–84 |year=2005 |pmid=15621994 |pmc=1356849 |doi= |url=}}</ref> | *[[CA 19-9]] is a protein released by cancers of the pancreas and bile ducts.<ref name="pmid15621994">{{cite journal |vauthors=Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, Suh KS, Lee KU, Park YH |title=Actual long-term outcome of extrahepatic bile duct cancer after surgical resection |journal=Ann. Surg. |volume=241 |issue=1 |pages=77–84 |year=2005 |pmid=15621994 |pmc=1356849 |doi= |url=}}</ref> | ||
*An elevated concentration of [[CA 19-9]] is suggestive of pancreatic cancer and cholangiocarcinoma. | *An elevated concentration of [[CA 19-9]] is suggestive of pancreatic cancer and cholangiocarcinoma. | ||
*CA 19-9 levels are not specific enough to be used as a screening test. | *CA 19-9 levels are not specific enough to be used as a screening test.<ref name="pmid14760772">{{cite journal |vauthors=Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR |title=Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA |journal=World J. Gastroenterol. |volume=10 |issue=3 |pages=427–32 |year=2004 |pmid=14760772 |pmc=4724921 |doi= |url=}}</ref> | ||
*It can be used as a tumor marker to determine response to chemotherapy. | *It can be used as a tumor marker to determine response to chemotherapy. | ||
Revision as of 15:41, 31 January 2018
Cholangiocarcinoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cholangiocarcinoma laboratory findings On the Web |
American Roentgen Ray Society Images of Cholangiocarcinoma laboratory findings |
Risk calculators and risk factors for Cholangiocarcinoma laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]
Overview
Laboratory tests for cholangiocarcinoma include carcinoembryonic antigen, carbohydrate antigen 19-9, and liver function tests.
Laboratory Findings
- Laboratory findings consistent with the diagnosis of cholangiocarcinoma include:
Liver function tests
- Patients with cholangiocarcinoma have elevated concentration of following tests, which is usually suggestive of cholestatic pattern:
- Prothrombin time
- Albumin and total protein
- Bilirubin
- L-Lactate dehydrogenase
- Alkaline phosphatase
- Gamma glutamyl transferase
- Alpha-fetoprotein
- Transaminase levels (aspartate aminotransferase (AST) and alanine aminotransferase (ALT)) may initially be normal among patients with cholangiocarcinoma.
Carcinoembryonic antigen
- Serum levels of carcinoembryonic antigen (CEA) are often elevated, but not sensitive or specific enough to be used as a screening test.
- It may be useful in association with imaging findings for suspected diagnosis of cholangiocarcinoma.[1]
Carbohydrate antigen 19-9 (CA 19-9)
- CA 19-9 is a protein released by cancers of the pancreas and bile ducts.[2]
- An elevated concentration of CA 19-9 is suggestive of pancreatic cancer and cholangiocarcinoma.
- CA 19-9 levels are not specific enough to be used as a screening test.[3]
- It can be used as a tumor marker to determine response to chemotherapy.
References
- ↑ Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients with and without primary sclerosing cholangitis include the following:
- Nehls O, Gregor M, Klump B (2004). "Serum and bile markers for cholangiocarcinoma". Semin Liver Dis. 24 (2): 139–54. PMID 15192787.
- Siqueira E, Schoen R, Silverman W, Martin J, Rabinovitz M, Weissfeld J, Abu-Elmaagd K, Madariaga J, Slivka A, Martini J (2002). "Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis". Gastrointest Endosc. 56 (1): 40–7. PMID 12085033.
- Levy C, Lymp J, Angulo P, Gores G, Larusso N, Lindor K (2005). "The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis". Dig Dis Sci. 50 (9): 1734–40. PMID 16133981.
- Patel A, Harnois D, Klee G, LaRusso N, Gores G (2000). "The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis". Am J Gastroenterol. 95 (1): 204–7. PMID 10638584.
- ↑ Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, Suh KS, Lee KU, Park YH (2005). "Actual long-term outcome of extrahepatic bile duct cancer after surgical resection". Ann. Surg. 241 (1): 77–84. PMC 1356849. PMID 15621994.
- ↑ Qin XL, Wang ZR, Shi JS, Lu M, Wang L, He QR (2004). "Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA". World J. Gastroenterol. 10 (3): 427–32. PMC 4724921. PMID 14760772.